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Abstract
Redox control is lost when the antioxidant defense system cannot remove abnor-
mally high concentrations of signaling molecules, such as reactive oxygen species
(ROS). Chronically elevated levels of ROS cause oxidative stress that may eventu-
ally lead to cancer and cardiovascular and neurodegenerative diseases. In this
review, we focus on redox effects in the vascular system. We pay close attention to
the subcompartments of the vascular system (endothelium, smooth muscle cell
layer) and give an overview of how redox changes influence those different com-
partments. We also review the core aspects of redox biology, cardiovascular physi-
ology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-
RedoxVasc was used to develop two case studies, one focused on endothelial cells
and the other on the vascular smooth muscle cells, as a starting point to possibly
extend our knowledge of redox control in vascular biology.
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1 | INTRODUCTION
Reactive oxygen species (ROS) and reactive nitrogen species
(RNS) stimulate redox homeostasis mechanisms, and thus, they
are considered critical signaling molecules for maintaining
cellular homeostasis. However, these signaling molecules can
be harmful, as well. That is, when ROS/RNS formation out-
paces the ROS/RNS removal processes, oxidative stress
(OxS) occurs. Chronic OxS leads to several pathologies.1,2 In
the vascular system, ROS is produced by the vascular smooth
muscle cells (VSMCs), endothelial cells (EC), and adventitial
cells, among others.3 The endothelium regulates the vascular
homeostatic system, as it is the barrier that separates blood
and tissue. However, when the antioxidant defense system
does not remove the excess ROS, it can cause endothelial dys-
function.4 This perturbation of the homeostatic functioning of
the vascular EC leads to pathologies such as tissue ischemia
and atherothrombosis.5 ROS is also involved in other patho-
physiological processes such as hypertension, inflammation,
and vascular remodeling,6–9 which leads to vascular patholo-
gies, including atherosclerosis, arterial hypertension, and car-
diovascular diseases (CVDs). Moreover, ROS-generating
systems also facilitate the development of diabetes mellitus,
obesity, and hypercholesterolemia, which increases the risk of
developing vascular pathologies.2
1.1 | ROS in general
Reactive species are molecules interacting with various bio-
molecules, including nucleic acids, lipids, and proteins, and
generating electron-deficient species, leading to cell and tis-
sue damages. Different endogenous metabolic and biochemi-
cal reactions and exogenous sources, such as ionizing
radiation, generate these reactive species. The term “reactive
oxygen species” refers to oxygen metabolites, such as super-
oxide anion radical (O2
•−), singlet oxygen (1O2), hydroxyl
radical (OH•─), and perhydroxyl radical (HO2
•), which are
yielded by the reduction of the oxygen molecule (O2) with
two uncoupled electrons.10–12 Furthermore, ROS with an
unpaired electron are free radicals; hence, they are also
named oxygen radicals or oxygen-free radicals,12 and free
radicals are chemical species that are capable of independent
existence with one or more unpaired electron. The unpaired
electron transforms the chemical reactivity of the molecule,
leading to its increased reactivity compared with the non-
radical form of the molecule.10,13 Thus, free-radical forms of
ROS can remove electrons from other molecules to gain sta-
bility and by that causes new free radical formation, initiat-
ing a chain reaction cascade, which consequently impairs
the cell/tissue functioning.14 In addition, the term ROS cover
all oxygen-containing reactive species, namely, alkoxyl radi-
cal (LO•), peroxyl radical (LOO⁃), lipid hydroperoxide
(LOOH), peroxynitrite anion (ONOO─), hypochlorous acid
(HOCl), and ozone (O3),
11–13 from which some are without
unpaired electrons (hydrogen peroxide (H2O2), ONOO─,
HOCl, and O3), and as such, they are not free radicals.
13
In biological systems, ROS produced by cellular metabo-
lism exert both deleterious, cytotoxic effects, as well as ben-
eficial effects13 such as antimicrobial activity,15 metabolic
pathways regulation,16 and cell signaling.17 Redox signaling
represents pathways in which ROS or some other reactive
species serve as messengers to induce cellular responses via
redox reactions, implicated in many different physiological
and pathological processes in the organism. Thus, ROS can
provoke redox modulation of protein kinase cascades and
transcription factors leading to different cellular responses,
such as cell proliferation and differentiation, altered expres-
sion, or synthesis of cytokine and/or adhesion molecules.12
Owing to the mostly deleterious nature of ROS, mammals,
including humans, have developed a robust antioxidant pro-
tection system through the action of enzymes such as Cu─Zn
superoxide dismutase (Cu─Zn SOD), catalase, glutathione
peroxidase, glutathione reductase, and glutathione-S-transfer-
ase. Moreover, several diet compounds, particularly from
fruits and vegetables, also exhibit antioxidant activities.12 An
imbalance between ROS generation and removal rate leads to
OxS,12 and chronic OxS leads to different pathologies, includ-
ing the vascular pathophysiology.1,2
1.2 | Vascular physiology in general
The vascular system is finely synchronized to adjust the blood
flow to the metabolic requirements of the body and is made up
of a heart and a closed network of vessels (arteries, veins, and
capillaries) that supply oxygen and nutrients to every tissue to
maintain cellular homeostasis. Endothelium lines the interior
surface of blood vessels—a single layer of homogenous EC
layer being in connection with blood and lymph from the cir-
culation and represents a surface (blood/endothelium interface)
with roughly 300–1,000 m2, whereas the mass is approxi-
mately 110 g.18,19 VSMC surround the endothelium, esta-
blishing the outer layer of arteries. The fibroelastic connective
layer and internal elastic lamina located below endothelium
provide flexibility and stability for EC. Perivascular cells (peri-
cytes) also surround the EC—multipotential stem cells with
the possibility to differentiate into different types of cells
among other VSMC, fibroblasts, osteoblasts, connective tissue
cells, and adipocytes, providing the EC and VSMC with a sta-
ble microenvironment and contractile ability.20
EC have a vital function in tissue homeostasis by the regu-
lation of solute and macromolecule transport through the ves-
sels. A glycocalyx layer on the EC surface provides a locally
charged barrier to cell and protein movement from the blood
through endothelium under physiological conditions.21 The
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endothelium also regulates and maintains vascular tone
through interaction with the peripheral nervous system and by
synthesizing and releasing vasodilatory factors such as
endothelin-1 (ET-1), thromboxane, endothelium-derived hyp-
erpolarizing factor, nitric oxide (NO), and prostacyclin.22
Another endothelium function is hemostasis regulation. That
is, the endothelium synthesizes compounds, which maintain
blood fluidity and are involved in the formation of non-
thrombogenic surface and coagulation processes. EC are
exposed to lipids (present in the circulation and accumulating
in the subendothelial regions) and are also involved in immu-
nological and inflammatory processes, which are associated
with atherosclerosis and occlusive vascular disorders.23
Furthermore, the endothelium is responsible for the reac-
tion to pathophysiological conditions such as infection or
trauma of the neighboring tissues, vessel remodeling, and
growth,24–26 therefore having significant diagnostic and ther-
apeutic potential. EC is capable of synthesizing most of the
proteins that constitute the basal lamina and enzymes
involved in extracellular matrix remodeling such as matrix
metalloproteinase (MMP), which is vital for the blood vessel
plasticity and angiogenesis.27 Thus, endothelium represents
an essential and dynamic endocrine organ due to its different
functions as alluded to above.
The fibrinolytic system is a system that restores a blood
vessel when the blood clot is not needed, and it includes an
inactive proenzyme, the plasminogen, and an active form,
plasmin that is responsible for fibrin degradation. The activ-
ity of plasminogen activators (PA) such as tissue-type PA (t-
PA) and urokinase-type PA (u-PA) regulates the fibrinolytic
potential of the vasculature.28 Activation of the EC and the
proinflammatory and procoagulant response lead to the syn-
thesis and release of u-PA.29,30 The constitutively produced
protein of EC, the PA inhibitor type I (PAI-1), suppresses t-
PA as well as u-PA. The activity of PAI-1 is an independent
risk factor for CVD.31 The EC synthesized and released
13-hydroxyoctadecadienoic acid, and the vasodilator factors
prostacyclin and NO, which prevents adhesion, aggregation,
and activation of platelets.32 EC also acts as a natural antico-
agulant by expressing the receptor for thrombin, the
thrombomodulin, responsible for thrombin conversion into
anticoagulant protein from a procoagulant protease. The
thrombin bound to thrombomodulin lids to protein C activa-
tion, which then binds to the endothelial protein C receptor.
Protein C (blood coagulation factor XIV or autoprothrombin
IIA) is an anticoagulant serine protease, which participates
in coagulation of the blood. Specifically, activated protein C
associates with its cofactor, protein S, and inhibit the coagu-
lation process through the inactivation of coagulation factors
FVa and FVIIIa.33 EC surface has heparin-like sulfated mol-
ecules of glycosaminoglycan, which bind/activate the anti-
thrombin that is the FXa and thrombin leading inhibitor.
Furthermore, the inhibition of the tissue factor-FVIIa
(TF-FVIIa) complex occurs by its interaction with a specific
polypeptide, the tissue factor pathway inhibitor (TFPI), and
formation of a stable quaternary complex TFPI-TF-FVIIa-
FXa.34 Thus, EC prevent blood clotting via a mechanism
that involves the heparin-like molecule thrombomodulin,
together with NO and prostacyclin. When an endothelial
injury occurs, EC stop the secretion of coagulation and
aggregation factors, and synthesize and secrete a large multi-
meric protein called the von Willebrand factor, which initi-
ates the hemostasis maintenance after injury.35 In addition,
EC produces the lipid-mediator platelet-activating factor,
which activates platelets and their attachment to EC.36
VSMC represent one of the most frequent types of cells in
arteries. VSMC are also essential for the homeostasis of the
vasculature, as well as for the vasculature contractions and
relaxations, which are responsible for the blood vessel luminal
diameter alterations to maintain blood pressure within the nor-
mal range. VSMC contractility is controlled regularly by
exchanging two different phenotypes.37 Different states of
VSMC are noted among both the VSMC of the same and var-
ious blood vessels. The mature, differentiated VSMC are con-
tractile, and their phenotype is elongated and spindle-shaped,
and these VSMC display low rates of migration and prolifera-
tion and express increased levels of proteins that are important
for contractility. VSMC shuttle to a dedifferentiated synthetic
phenotype with rhomboid shape in certain physiological con-
ditions, including pregnancy or exercise, and after injury of
the vasculature, which is vital during vessel remodeling.38
Dedifferentiated VSMC are exceptionally proliferative and
migratory, and synthesizes extracellular matrix proteins, like
elastin and collagen.39 Based on all these properties, VSMC
are capable of regulating the vessel diameter in short terms
and in long terms VSMC are responsible for adaptation by
structural remodeling through changing the number of cells
and the constitution of connective tissue. The VSMC marker
proteins that are most significant in defining VSMC pheno-
types include cellular retinol binding protein-1, smooth mus-
cle myosin heavy chain (SM-MHC), α-smooth muscle actin,
SMemb/nonmuscle MHC-B, and smoothelin A and B.38 A
few of these proteins are structural components of the contrac-
tile apparatus or act as the contraction regulators. Generally,
the loss of proteins essential to the contractile phenotype indi-
cates the synthetic phenotype. The expression of the two
marker proteins, SM-MHC, and smoothelin, characterizes a
mature contractile VSMC phenotype.40
2 | EFFECTS OF ROS
The human body uses a cellular antioxidant defense
system to neutralize free radicals and, consequently, OxS.
In OxS, ROS are involved directly or indirectly in the
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macromolecules deterioration, along with oxidative deterio-
ration of nucleic acids, proteins, and lipids.41 However,
ample evidence suggests that ROS directly activate OxS-
responsive pathways regulating different cellular processes,
additionally leading to the progression of diseases. OxS is
associated with carcinogenesis,42 neurodegeneration,43 ath-
erosclerosis, diabetes,3 and aging.44 ROS are also critical
physiological modulators of the redox state signaling mole-
cules.45 ROS changes the function of the protein by the
mechanism that includes the modifications of cysteine (Cys)
residues, which are redox-reactive. Cys residue oxidation
promotes the formation of reactive sulfenic acid (─SOH)
that can interact with nearby Cys-forming disulfide
(─S─S─) bonds or endure additional oxidation to sulfinic
(─SO2H) or sulfonic (─SO3H) acid.
46 These modifications
(except sulfonic acid and to a lower extent sulfinic acid)
reverse specific reducing systems including peroxiredoxin
and thioredoxin, suggesting that these modifications are
involved in redox sensing and signaling and regulation of
protein structure/function.47 Numerous studies show that
ROS influence many different signaling pathways involving
molecules, such as tyrosine and Rho kinases, mitogen-
activated protein (MAP) kinases, transcription factors (HIF-
1, nuclear factor-kappaB [NF-κB], and activator protein-1
[AP-1]), as well as protein tyrosine phosphatases (PTPs)
involved in cardiovascular, neural, and renal cell func-
tion.48,49 ROS elevates the concentration of intracellular free
Ca2+ ([Ca2+]i) by the activation of ion channels, and ROS
upregulates the expression of proinflammatory and proto-
oncogene genes (Figure 1).50
3 | REDOX SIGNALING IN THE
VASCULAR PATHOPHYSIOLOGY
In vascular tissue, diverse systems generating ROS interre-
late to establish a combined redox modulation.51 Nonethe-
less, the majority of tissue damage and pathology is a result
of excessive ROS production, which leads to inflammation
in the vascular tissues, while excessively low levels of ROS
interrupt the oxidant physiological role in vasodilation and
cellular growth.52 Furthermore, it has been suggested that
“intermediate” ROS levels could facilitate the physiological
response in the vasculature, while chronically elevated ROS
level characteristic for OxS could be associated with CVD.53
Hence, ROS participate in the pathophysiology of the vascu-
lar disease, but also regulate vascular function in healthy
vessels54 (Table 1). In addition, ROS is part of an adaptive
response in vascular diseases.87 In Table 2, we summarized
some of the effects of ROS on vascular physiology in animal
and human studies. These distinctive roles of ROS may be a
consequence of the different physicochemical properties of
ROS. For example, H2O2 biological half-life is expanded
compared with the half-life of O2
− and OH− and can diffuse
through lipid membranes, and the charge of the O2
− mole-
cule prevents it from crossing the cell membranes except for
the possibility to cross the membrane through ion channels.3
Besides, reductive stress (RS) is another deleterious factor
that disturbs the redox state and promotes vascular
pathophysiology.103–105 Furthermore, RS increases s-
glutathionylation of proteins, and that may be involved in
FIGURE 1 Effects of ROS in
physiological and pathophysiological
conditions
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uncoupling of eNOS that elevates O2
− production and
induces OxS.103–106
3.1 | Xanthine and NAD(P)H oxidase as the
culprit of ROS in vascular pathophysiology
The most prominent origins of ROS in the vascular tissue
are xanthine oxidase (XO) and NAD(P)H oxidase. NAD(P)
H oxidase regulates the conversion of xanthine dehydroge-
nase (XDH) to XO. The modulation of XDH to XO reduces
oxygen to O2
− and H2O2. XO regulates the oxidation pro-
cess of hypoxanthine and xanthine and generates O2
− in the
vascular endothelium.3,107
The increase in XO activity has been associated with
endothelial dysfunction in rats overexpressing renin and
angiotensinogen from implanted human genes.88 On the
TABLE 1 Some ROS species important for vascular physiology and pathophysiology
ROS
Mechanism of
generation/enzymatic source Physiological concentrations Reference Elevated concentrations Reference
•O2 • The electron transport chain
of mitochondria
• EC growth, proliferation,
survival, and angiogenesis
55 • Enhanced vasoconstriction
• Impaired vasorelaxation
• Decreased sGC
activity/expression
• Vascular remodeling
• Sympathetic activation
• Endothelial dysfunction
• Peripheral resistance
• DNA damage
• EC apoptosis
• VSMC hypertrophy
• VSMC matrix regulation
• Hypertensions
• Atherosclerosis
56,57
57
57
58–61
57
57,58
57
57
62
62
62
58,60,63,64
58,65
• Monooxygenase • Contraction–relaxation
• NADPH oxidase • Maintaining cardiac and vascular
integrity
56
• Xanthine oxidase
• Lipooxygenase
• eNOS uncoupling
58
H2O2 • From •O2 by SOD • EC growth, proliferation,
survival, and angiogenesis
• Endothelium-dependent
vasorelaxation
• Cytoskeletal reorganization of EC
• Inflammatory responses of EC
• Endothelium-regulated vascular
remodeling
• Vasodilation
• Synthesis/release of endothelium-
derived relaxing factor
55,66 • Impaired proliferation and/or
decreased viability of EC
• EC apoptosis
• VSMC hypertrophy
• VSMC proliferation
• VSMC matrix regulation
 VSMC apoptosis
• Vascular relaxation and
hyperpolarization
 Hypertension
• Atherosclerosis
55,67
62,68
55,62,69
62
62
62
54,70,71
62
62
• Directly produced by: 55
• Glucose oxidase 55
• Xanthine oxidase 55
• -NADPH oxidase 4 isoform 55
55,72–76
77
•OH • Produced in Haber–Weiss
reaction from •O2 and H2O2
from reactions with
hypochlorous acid
• Vasodilation
• VSMC relaxation
• Synthesis/release of endothelium-
derived relaxing
77
77
77
• Atherosclerosis
• Lipid peroxidation
78
79
ONOO− • Produced in reaction of NO
and •O2
• Regulation of vascular
contraction/relaxation
• Trigger stress adaptation
• Protection of vascular
endothelium
80
81
82
• Impairment of vascular
relaxation by various
mechanisms
• EC and VSMC apoptosis
• Peripheral vascular failure
• Lipid peroxidation
• Oxidation of BH4
• Oxidation of sGC
• Oxidative DNA damage
• Endothelial dysfunction
83,84
84–86
84
57
57,84
57
84
84
Note: Under physiological conditions, ROS in the vasculature are produced in a controlled manner at low concentrations and function as signaling molecules. Increased
ROS production leads to pathological conditions of vascular system.
Abbreviations: •OH, hydroxyl radical; BH4, tetrahydrobiopterin; EC, endothelial cell; eNOS, endothelial nitric oxide synthase; H2O2, hydrogen peroxide; NADPH,
nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; O2, superoxide anion; ONOO
−, peroxynitrite; sGC, soluble guanylate cyclase; SOD, superoxide
dismutase; VSMC, vascular smooth muscle cells.
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TABLE 2 The effects of ROS on vascular physiology- animal and human studies
Effects of ROS Condition and/or treatment Species Ref.
• Endothelial dysfunction " OxS
" XO activity • Ang II-induced vascular
dysfunction
dTGR
SDR
88
• " Arteriolar tone " XO activity SHR 89
• Correct hypertrophy of renal and
cardiac tissue
" XO activity • Allopurinol
• Sodium restriction
SHR
DSS rats
90,91
• " Systolic blood pressure
• Endothelial dysfunction
• Vascular hypertrophy
" O2−
" p22phox mRNA
• Irbesartan SHR
WKY
92
• Atherosclerosis " ROS • Ang II-mediated MAP kinase
activation
Rat VSMC 93
• " Systolic blood pressure " O2− • Ang II-induced hypertension 94
• Stimulate vascular smooth muscle
cell growth
"H2O2
"O2−
• Naphthoquinolinedione
LY83583
95
• # Expression of proinflammatory
molecules
" O2− • Angiotensin receptor inhibition
• gp91phox NAD(P)H oxidase
inhibiton
Hypertensive
DSS rat
58
• # Vascular superoxide production " superoxide production
" ET-1
• ETA receptor inhibition DOCA-salt hypertensive
mice and rats
96,97
• Attenuated blood pressure
elevation
" O2− • Ang II–induced hypertension
• Inhibited association of p47phox
and gp91phox
Mice/
Aortic rings
46
• " Mean blood pressure Nox1(+/Y)
• # Production of superoxide in
Nox1(−/Y)
• Preserved endothelium-dependent
relaxation in Nox1(−/Y)
" ROS • Ang II-induced hypertension Nox1-deficient
(−/Y) mice
98
• " Systolic blood pressure
• " Aortic hypertrophy
• Development of cardiovascular
pathologies
" superoxide production VSMC TgSMCnox1 99
• No changes in blood pressure of
p47phox−/−deficient mice after Ang
II tratment
" O2− p47phox−/−deficient mice 63
• # Aneurysm formation
• # NOx levels
" ROS • NADPH oxidase inhibition iNOS−/− mice 100
• Dysfunction of the endothelium
• Vascular remodeling
- • ET-1 overexpression C57BL/6 TG and
WT mice
101
• # NO levels " O2− production • PMA stimulation Hypertensive and
normotensive patients
102
• "Oxidized/reduced glutathione
ratio
• # Activity of superoxide dismutase,
catalase, and glutathione
peroxidase
• Development of cardiovascular
complications
" ROS - Hypertensive and
normotensive patients
53
Abbreviations: ", increased; # decreased; Ang II, angiotensin II; DOCA, salt-deoxycorticosterone acetate-salt; DSS, Dahl salt-sensitive; dTGR, double-transgenic rats;
ET-1, endothelin-1; iNOS−/−, iNOS-deficient; ONOO−, peroxynitrite; OxS, oxidative stress; PMA, phorbol myristate acetate; SDR, Sprague Dawley rats; SHR,
spontaneously hypertensive rats; TG, transgenic; TgSMCnox1, transgenic mice overexpressing Nox1 in smooth muscle cells; VSMC, vascular smooth muscle cell;
WKY, Wistar-Kyoto rats; WT, wild type (nontransgenic); XO, xanthine oxidase.
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other hand, in spontaneously hypertensive rats (SHR),
increased activity of XO was found in the microcirculation
of the mesentery.89 The increased XO activity has also been
found in the renal tissue of SHR and Dahl salt-sensitive
(DSS) rats, while the discovery that allopurinol can correct
the hypertrophy of renal and cardiac tissue in SHR without
lowering the blood pressure implies the involvement of XO
in organ damage induced by elevated blood pressure.90,91
Models for ischemia–reperfusion injury and heart failure
also demonstrated the involvement of XO.3
NAD(P)H oxidase is an enzyme complex that uses
NADH/NADPH as the donor of an electron in the reduction
of O2 and consequent formation of superoxide. The
membrane-bound p22phox subunit is crucial for the NAD(P)H
oxidase complex activation and is accompanied by an ele-
vated production of O2
− in humans with coronary artery dis-
ease.108 The increased levels of OxS byproducts, together
with elevated oxidative DNA damage, were found in samples
obtained from patients with arterial hypertension.53
The mononuclear cells isolated from the blood of patients
with essential hypertension exhibited increased O2
− produc-
tion after treatment with angiotensin II (Ang II) or ET-1 when
compared with controls.102 The majority of studies investigat-
ing NAD(P)H oxidase activation in vascular cells focused on
Ang II signaling, which implicates receptor tyrosine kinases,
protein kinase C, c-Src, and phospholipase D.109 The expres-
sion/activity of NAD(P)H oxidase was found to be increased
in rats with hypertension caused by Ang II treatment.94 A
NAD(P)H oxidase inhibitor, decreasing both vascular O2−
synthesis and hypertension in mice, supports this finding.110
The NAD(P)H oxidase Nox1 isoform participates in the Ang
II-induced hypertensive response. The reduced production of
O2
− and the blunted effect of Ang II on the blood pressure
were both found in Nox1-deficient mice.98
On the other hand, the overexpression of Nox1 enhances
Ang II-induced O2
− formation, VSMC hypertrophy, and
hypertension in transgenic mice.99 Furthermore, in cytosolic
NAD(P)H p47phox subunit-deficient mice, the endothelial
dysfunction, O2
− production, and Ang II-induced hyperten-
sive response were blunted.63 Moreover, NAD(P)H oxidase
was associated with raised O2
− production in the arterial tis-
sue of SHR.92
The produced ROS from NAD(P)H can react with products
of nitric oxide synthase (NOS), which may further amplify
vascular function. For example, O2
− generated from NAD(P)
H oxidase reacts with NO, forming peroxynitrite (ONOO−),
which consequently induces changes in the NOS enzyme sub-
units resulting in further O2
− formation and the declination of
NO bioavailability, which impairs endothelium-dependent
relaxation in a model of salt-induced hypertensive rats.111
ROS synthesized by NAD(P)H oxidase is required for iNOS
expression in microvascular EC.112
The membrane-bound gp91phox-containing NAD(P)H oxi-
dase is identified as a source of excessive O2
− linked with ele-
vated activity of the renin–angiotensin system as shown in
renovascular113 and salt-induced hypertension114 models.
Treatments with the angiotensin receptor blocker and with
the gp91phox NAD(P)H oxidase inhibitor restrained the ele-
vated O2
− aortic generation and the expression of the
proinflammatory molecules in a model of hypertensive DSS
rats. Importantly, ROS-induced injury was shown to lead to
further ROS formation while proinflammatory cytokines acti-
vated the system of NAD(P)H oxidase.58 The JAK/STAT cas-
cade, which regulates the transcription of proinflammatory
genes, is also upregulated by ROS synthesized by the Ang II
and platelet-derived growth factor (PDGF) activity. Inhibition
of the NAD(P)H oxidase subunit p47phox inhibits Ang II-
induced activation of JAK/STAT signaling and interleukin-6,
which suggests that the NAD(P)H oxidase activity generates
the ROS involved in this pathway.115
Furthermore, ROS produced at one subcellular locus can
initiate ROS synthesis in another locus by signal transmis-
sion. For example, mitochondria-derived ROS production
activates ROS formation by NAD(P)H oxidase.116 The
NAD(P)H oxidase increased activity in pulmonary micro-
vascular EC produces extracellular O2
−. The extracellular
O2
− moves through chloride channel 3 into cells, where it
triggers Ca2+ mobilization and mitochondrial O2
− produc-
tion. Thus, ROS generated from endothelial NAD(P)H oxi-
dase mediates intracellular signaling.117,118
The ET-1 also induces an increase in ROS generation by
the activation of NAD(P)H oxidase pathway. ET-1 via ETA
receptor activation increases O2
− production in the DOCA-
salt hypertensive rat model, while the ETA receptor inhibition
decreases the production of vascular superoxide.96,97 More-
over, endothelium-restricted human ET-1 overexpression was
shown to cause dysfunction of the endothelium and vascular
remodeling in mice through the NAD(P)H oxidase path-
way.101 Besides, NAD(P)H oxidase pathway, dysfunction of
endothelium, and vascular remodeling can be the result of an
activated extracellular signal–regulated kinases (ERK) signal-
ing pathway. Numerous studies have shown that increased
level of oxLDL induces accumulation of ROS, which stimu-
lates ERK phosphorylation, upregulates the expression of
endothelial transcriptional factor AP-1 and ET-1, and, conse-
quently, promotes the progression of atherosclerosis.119–121
Activation of NAD(P)H oxidase is also involved in the
pathogenesis of abdominal aortic aneurysm. That is, samples
obtained from subjects suffering from aneurysms of the
abdominal aorta exhibit overexpressed NADPH oxidase and
raised level of O2
− in the endothelium and within the aortic
wall. ROS synthesized by the NAD(P)H oxidase activity
facilitate the inflammatory process in the aortic endothelium
and stimulate the extracellular matrix impairment through
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the MMP-2 activation and apoptosis of VSMC. A murine
aneurysm model was used to show that inhibition of ROS
mitigates the formation of the aneurysm.100 Also, the cyclic
stretch of VSMC stimulates the expression of MMP-2. This
response is blunted in murine cells deficient in the p47phox
subunit of NAD(P)H oxidase, thus implying the function of
ROS generated by the NAD(P)H oxidase in MMP-2 signal-
ing in VSMC.122 Moreover, Ang II induces MMP-2 via the
p47phox subunit.123 Also, ROS generated by macrophage-
derived foam cells modifies the activity of MMP-2 and
MMP-9 in vitro.124
Various growth factors (such as PDGF and transforming
growth factor β) and hormones are involved in the modula-
tion of NAD(P)H oxidase activity/expression, while ROS
regulates the activity of many signaling enzymes (tyrosine
and MAP kinases, PTPs) in the vasculature.3 Redox signal-
ing also mediates the activity of transcription factors in the
vascular cells. In addition, the laminar flow and the shear
stress influence the ROS activity in both physiological and
pathophysiological settings.
3.2 | The effects of ROS on tyrosine and MAP
kinases, and PTPs in vascular pathophysiology
ROS regulates the tyrosine kinases (receptor and nonreceptor
forms) in the vasculature. Receptor tyrosine kinases, PDGF
receptor beta (PDGFR-β), and the epidermal growth factor
receptor (EGFR) require ligand-stimulated signal transduc-
tion. It appears that H2O2 generation is mandatory for signal
transmission through PDGFR-β.125,126 Furthermore, Ang II
stimulates EGFR and PDGFR-β through transactivation. The
nonreceptor tyrosine kinase Src also contributes to the H2O2-
dependent Ang II-stimulated EGFR transactivation.127 Acti-
vation of tyrosine kinases regulates NAD(P)H oxidase, which
additionally amplifies ROS production in the vascular tissue.
The transactivation of EGFR and PDGFR-β stimulates MAP
kinases in VSMC.128
PDGF and Ang II activate MAP kinases in the vascular
tissue.129 H2O2 and O2
− activate MAP kinases in VSMC.95
H2O2 stimulates p38 MAP kinase, required for redox-
sensitive signal transduction initiated by Ang II in VSMC.130
ROS implicated in MAP kinase activation induced by Ang II
has also been derived from NAD(P)H oxidase in VSMC.93
Protein tyrosine phosphorylation is also affected by ROS.
Protein tyrosine kinases (PTK) and PTPs regulate tyrosine
phosphorylation. The complex of PTP enzymes dephosphor-
ylates PTK substrate proteins and counteracts PTK activity.
Both receptor and nonreceptor PTPs are susceptible to O2
−
and H2O2. Exposure of cells to ROS inactivates PTP through
oxidation of Cys residue in its structure and increases protein
phosphorylation.131 However, this process is reversible, and
PTPs is present in two states, either with a reduced or with
oxidized Cys. Ang II may influence the oxidation of PTP-
activated NAD(P)H oxidase and O2
− generation.132,133 Also,
Ang II stimulates the expression of the vascular cell adhe-
sion molecule-1 via NF-κB activation through ROS
signaling.134
3.3 | ROS-induced activation of transcription
factors in vascular pathophysiology
The activation of ROS by NF-κB occurs through the activa-
tion of inhibitory κB kinases. The NF-κB signaling modulates
the expression of genes involved in inflammation and stimu-
lates the ROS generation. In diabetic mice, the activation of
NF-κB increased the generation of the proinflammatory cyto-
kine, the tumor necrosis factor-alpha, which in turn elevated
O2
− production by NAD(P)H oxidase.135 Ang-II stimulated
endothelial ROS generation through the stimulation of NF-κB
signaling pathway in DSS rats.136 One of the sources of ROS
(O2
− and H2O2) generated through NF-κB signaling is
NAD(P)H oxidase. The NF-κB cis-acting elements regulate
the promoter of p22phoxNAD(P)H oxidase gene in human aor-
tic smooth muscle cells.137 The findings that revealed that
NF-κB enters the mitochondria of the obese mouse with dia-
betes and increases mitochondrial O2
− suggest the non-
transcriptional role of NF-κB in ROS production.138 Since
NF-κB activity leads to elevated ROS production, while ROS
activates NF-κB, the ROS generated by NAD(P)H oxidase
will upregulate NF-κB, initiating a positive feedback mecha-
nism for ROS generation.108
4 | HEMODYNAMICS AND REDOX
SIGNALING
Redox signaling likely also influences the mechanical
forces acting on the vascular wall. That is, elevated
intraluminal flow stimulates the generation of O2
− and
H2O2 in intact blood vessels. In VSMCs, shear stress was
demonstrated to induce ROS generation.139 The ROS activ-
ity in cultured EC during oscillatory shear stress is derived
from the activation of XO. The attenuation of O2
− produc-
tion in the vasculature affected by oscillatory shear was
found in cells lacking NAD(P)H oxidase activity, or by
application of oxypurinol, a specific blocker of XO.107
However, the exact mechanism is still undetermined and
may implicate NAD(P)H, and XO and/or mitochondrial
enzymes.132 Laminar shear upregulates the expression of
the extracellular SOD and cytosolic copper and zinc SOD
in human aortic EC, and may regulate protective vascular
response.140 Finally, ROS, particularly O2
− and H2O2, can
diminish the efficacy of the antioxidant system, leading to
the promotion of OxS. These signaling molecules play a
significant role in the pathophysiology of the vasculature.
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5 | DEVELOPING LEADS TO
EXTEND OUR UNDERSTANDING OF
REDOX CONTROL OF VASCULAR
BIOLOGY
Data-mining and text-mining techniques have been used to
explore the information contained in published biomedical
literature. Advancements in these techniques have led to the
development of several topic-specific knowledgebases
(KB),141–159 including the first topic-specific KB for redox
control of vascular systems, named DES-RedoxVasc.160
DES-RedoxVasc was constructed using the search query:
(human OR mouse OR rat OR mammal*) AND (radical*
OR peroxide* OR “reductive stress” OR ROS OR “reactive
oxygen species” OR RNS OR “reactive nitrogen species”
OR redox OR “reduction–oxidation reaction” OR oxidative
OR nitrosative OR peroxide* OR superoxide* OR detoxifi*
OR antioxid* OR “polyunsaturated fatty acids” OR
“arachidonic acid” OR “linoleic acid” OR hydroperoxide*
OR “hypochlorous acid” OR peroxynitrit* flavoprot* OR
xanthine oxidase* OR “cytochromes P450” OR catalase*
OR sulfiredoxin* OR peroxiredoxin*) AND (“angina
pectoris” OR anemia OR aneurysm* OR angio* OR arter*
OR atrial OR atrioventricular OR aort* OR bradycardia OR
blood OR brain OR circulati* OR clogging OR cardio* OR
coronary OR edema OR heart OR ischemic OR hemo* OR
hypertension OR leukemia OR leuko* OR macroangiopathy
OR microangiopathy OR neovascularization OR occlusion
OR pericardi* OR sepsis OR “sickle cell” OR tachycardia
OR tachyarrhythmia OR thromb* OR vaso OR vein* OR
ventricular OR vascular* OR vessel*) to retrieve all litera-
ture specifically focused on research related to redox effects
on the cardiovascular system in mammalian organisms. This
allowed for the retrieval and analyses of published informa-
tion from 2330399 PubMed (based on article abstracts) and
PubMed Central documents (based on the complete text in
the article) linked to redox processes in the cardiovascular
system. Users can easily explore the analyzed documents in
DES-RedoxVasc through links between various concepts
from 28 topic-specific dictionaries such as pathways, diseases,
genes/proteins, miRNAs, toxins, drugs, biological processes,
molecular functions, and so on. DES-RedoxVasc can be used
to search for hypotheses and potentially new knowledge in
vascular biology. A published example in 160 shows that the
semantic similarity tool in this KB linked ZFAS1 (long non-
coding RNA) and miR-27b, even though there is no literature
linking the functioning of miR-27b and ZFAS1. Nonetheless,
miR-27b and ZFAS1 are linked to different vascular patholo-
gies, and the DIANA tool, LncBase Predicted v.2,161 predicts
that ZFAS1 binds hsa-miR-27b-3p, which supports the possi-
bility that the link suggested by DES-RedoxVasc may be cor-
rect. The possible role of ZFAS1 in the fine tuning of levels
of miR-27B, a microRNA that is known to be responsive to
OxS, has not been explored.160 As a consequence, we used
DES-RedoxVasc to develop additional case studies.
Case Study 1: Here, we characterize the biological func-
tions of VSMC relative to chemical substances in the litera-
ture in connection with both VSMC and gene ontology
biological functions that were associated with VSMC. As
such, Figure 2 gives an overview of substances that are vital
for homeostasis or can disturb the proper functioning
of VMSC
The following redox-related molecules discussed in this
manuscript were retrieved: “oxygen radical,” “superoxide,”
and “hydrogen peroxide.” However, DES-RedoxVasc points
out additional molecules that should be explored (via https://
www.cbrc.kaust.edu.sa/des-rv/) in this context. For instance,
it would be interesting to look at the relationship between
“H2O2” and “Ang II,” as Ang II and other chemotactic fac-
tors are dependent on H2O2 for their release.
162 It is there-
fore of interest knowing which GO terms are linked to both
H2O2 and Ang II. In the DES-RedoxVasc KB, they are
linked to vasodilation, vasoconstriction, macrophage activa-
tion, as well as VSMC that were the starting point of this
exploration.
Case Study 2: Studies have demonstrated that both dietary
PUFA and fish oils exhibit a protective role in CVD.163–166
PUFAs provide several benefits including modulating lipid
metabolism, reducing the production of inflammatory cyto-
kine, and facilitating improvements in vascular EC func-
tion.167 PUFAs also transiently increase the levels of ROS
that activate the OxS-response transcription factor NFE2L2/
NRF2 (nuclear factor, erythroid derived 2, like 2) in pigment
epithelial cells from the human retina,168 which transcribe
several antioxidant genes. PUFAs were also shown to modu-
late noncoding RNAs169,170 that may be the mechanism used
to mediate the chemoprotective and antioncogenic properties
of PUFAs. Thus, we here also used DES-RedoxVasc to
explore the microRNAs linked to vascular ECs, OxS
response, and n-3 polyunsaturated fatty acids (PUFA) (see
Figure 3). We start this exploration by clicking the “Enriched
Concepts” link in DES-RedoxVasc. On this page, we used
the search bar to filter the concept “vascular endothelial cell,”
and then used this concept right-click menu to generate a net-
work (see Figure 3). On the “Network” page, we selected four
dictionaries including “HFO Ontology (Bioportal) Heart Fail-
ure Ontology,” “Pathways (KEGG, Reactome, UniPathway,
Panter),” and “Human microRNAs” dictionaries. Then, the
“vascular endothelial cell” node was highlighted to expand
the associated concepts with links from the selected dictionar-
ies. Then, we only selected the “Human microRNAs” dictio-
nary (as microRNAs linked to vascular ECs, OxS response,
and PUFAs are the focus of this case study), and highlighted
the “Oxidative stress response” node to expand/link the
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associated concepts from the “Human microRNAs” dictio-
nary. We repeated this step for other nodes including the
“Polyunsaturated Fatty Acids,” “MIR3178,” and “MIR937.”
All additional nodes with two or more edges (“MIR34A,”
“MIR20B,” and “MIR7A2”), generated in step 3, were also
expanded/linked with their associated concepts in the “Human
microRNAs” dictionary. We then pruned the nodes using the
connectivity threshold of 2 (see Figure 3).
Several of the noncoding RNAs (“MIR15B” [miR-15b],
“MIR16” [miR-16], “MIR17” [miR-17], and “MIR20B”
[miR-20b]) retrieved by DES-RedoxVasc are modulated by
PUFAs. That is, three different PUFA-treated glioblastoma
cell lines consistently exhibited an increase in the levels of
miR-20b, and decreased levels of microRNA (miR-16 and
miR-17) that induces apoptosis-specific expression changes.169
In addition, the level of miR-15b increases in rats injected with
the colon carcinogen and azoxymethane, and fed by fish oil/n-
3 PUFA rich diets.171
This report by 171 is interesting as the generation of mito-
chondrial ROS is promoted by miR-15b, as well as mito-
chondrial dysfunction, through the inhibition of SIRT4
(exclusively localized in mitochondria).172 SIRT4 is also
associated with photoaged skin and stress-induced cellular
senescence, which linked senescence-associated mitochon-
drial dysfunction to both miR-15b and SIRT4.173 Moreover,
miR-20b upregulated by PUFAs directly targets AKT3, and
AKT3 silencing decreases the levels of VEGF.174 Specifi-
cally, in primary ECs, VEGF stimulation and the down-
stream mitochondrial biogenesis process required AKT3,
and the blockade of AKT3 also reduces PGC-1α-dependent
gene expression.175 This suggests that even though mito-
chondrial biogenesis is tightly interlinked to antioxidant
receptor transactivation
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systems, both miR-15b and miR-20b prevent mitochondrial
functioning under unregulated OxS conditions. This
decrease in mitochondrial biogenesis substantially decreases
dysfunctional mitochondria produced by excessive ROS,
which can be viewed as a quality-control process.
Figure 3 further shows that both the “MIR20B” and
“VASCULAR ENDOTHELIAL CELL” nodes are further
linked to two additional microRNAs, “MIR3178” (miR-
3,178) and “MIR937” (miR-937), which suggest that they
may function in the same or a closely linked mechanism.
For now, we know that the levels of miR-20b, miR-937, and
miR-3,178 are upregulated in a human vascular EC line
(EAhy926) infected with the DENV-2 (TR1751 strain),176
which may be a consequence of a mechanism counteracting
the DENV infection-induced OxS.177
6 | CONCLUDING REMARKS
Endothelial ROS production has a prominent role in regulat-
ing the vascular redox homeostatic mechanisms in the vas-
cular system. By understanding the ROS/RNS removal
processes, we may influence the overall perturbing homeo-
static functioning of the vascular endothelial system and the
underlining consequence of a disbalance portraying as OxS
in which it elevates inflammation and vascular remolding,
activating the events for CVD.
The most prevailing players in vascular ROS pathology
are XO and NAD(P)H oxidase, with links to various models
of heart failure, ischemia injury, and DNA damage in
patients with arterial hypertension, and so on. Interestingly,
NAD(P)H was found to be in an ROS MMP-2 signaling
pathway in VSMC, suggesting some interwoven pathways
of redox signaling, PTK and phosphatase activation, growth
factors, vasoactive hormones, and transcription factors. To
broaden our understanding of the redox control of the vascu-
lar endothelial system, we used text mining and data mining
techniques to explore new intricacies of information embed-
ded in the biomedical literature that we may not be aware of
at first glance. By retrieving redox relating molecules from
the DES-RedoxVasc, we established new links and relation-
ships between different components, such as with hydrogen
peroxide and with Ang II. The results also suggest an over-
lapping interplay of processes that connect mitochondrial
biogenesis and antioxidant systems with miR-3178 and
miR-937. This shows that a cell expresses a quality control
mechanism in the Redox homeostatic mechanisms of the
vascular endothelial system. By using data mining in a
review process, we have also deepened our understanding to
our view the intricacies of how ROS is utilized in the vascu-
lar endothelial system redox system and also easier to see
new pathways for improved treatment and more adequate
prevention of cardiovascular-related diseases.
FIGURE 3 DES-RedoxVasc network illustrating microRNAs that may affect the relationship among “VASCULAR ENDOTHELIAL CELL”,
“Oxidative stress response”, and “Polyunsaturated Fatty Acids.” The orange circles denote concepts from the “human microRNAs” dictionary; the
green circles denote concepts from the “HFO Ontology (Bioportal) Heart Failure Ontology” dictionary; the blue circles denote concepts from the
“Pathways (KEGG, Reactome, UniPathway, Panter)” dictionary; and the red circles denote concepts from the “Human Anatomy” dictionary
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